Skip to main content
. 2021 Jun 1;106(9):e3346–e3363. doi: 10.1210/clinem/dgab387

Figure 6.

Figure 6.

DNA methylation in first and second promoters correlates with pituitary adrenocorticotropin (ACTH)-secreting tumor characteristics. DNA methylation levels in first (hPro1) and second (hPro2) promoters were analyzed by bisulfite-conversion–based methylation-specific polymerase chain reaction based on A, ubiquitin-specific protease 8 (USP8) mutation status (USP8 wild-type [WT] (n = 26) vs USP8 mutated [mut] (n = 6), *P = .0029); B, tumor size (microadenoma [micro < 10 mm] (n = 12) vs macroadenoma [macro ≥ 10 mm] (n = 20), *P = .0383); C, recurrent disease (nonrecurrent [not recur] (n = 24) vs recurrent [recur] (n = 8), *P = .007); D, Crooke cell changes (absent [non-Crooke] (n = 22) vs present [Crooke] (n = 10), *P = .0006); E, sex (male [n = 10] vs female [n = 22]); and F, age (< 40 [n = 12] vs ≥ 40 years [n = 20]). Characteristics of all 32 ACTH-secreting pituitary tumors are given in Table 3.